Auto-injector platform company Pirouette announced they had surpassed $5 million raised in their community investment round via Wefunder, leading them to extend the round due to overwhelming demand. This extension gives the millions that this solution is designed to help more time to invest and accelerate the pathway to making it available. This is a rare opportunity to join along renowned investors like Safar Partners, Liquid 2 Ventures, and Gaingels.
Headed by a team of rocket scientists from MIT, Harvard Medical School, Harvard Business School, Clarkson University, General Electric, and NASA, Pirouette is set to transform drug administration – simplifying life-saving injections such as Epinephrine for severe allergies and Naloxone for opioid overdose.
With 21 patents awarded and additional filings happening, the round has captured the attention of industry leaders and investors, recognizing Pirouette’s potential to transform the injectables industry. And the company’s goal to simplify injectable treatments aligns with the growing demand for patient-centric healthcare solutions.
Pirouette’s funding round is still open to the public for a limited time through Wefunder, the leading platform for early-stage retail investing, with an opportunity for anyone who is impacted or has a loved one who is impacted to invest and own a stake in the company.
KEY QUOTES:
“We are overjoyed by the enthusiasm and support from our community of investors. With severe allergies on the rise and the opioid crisis escalating, this touches everyone, and the need for our innovative autoinjector has never been greater.”
– Conor Cullinane, PhD, CEO and Co-founder of Pirouette Medical
“This funding is a crucial step towards bringing our groundbreaking device to market, aiming to enable life-saving medications that are within easy reach of those in need.”
– Matthew Kane, The COO of Pirouette Medical
